Although funds have not been appropriated for the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP), the ALSRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.
Anticipated Award Mechanisms
Therapeutic Development Award
Supports post-discovery, pre-clinical development of therapeutics for ALS.
- Eligibility: Independent investigators at all academic levels
- Funding: Maximum funding of US $1M (approx AUD $1.3M) for direct costs (plus indirect costs)
- Duration: Maximum period of performance is 2 years
Impact Award
Supports hypothesis-driven drug discovery efforts focused on ALS therapeutics
- Eligibility: Independent investigators at all academic levels
- Funding: Maximum funding of US $500,000 (approx AUD $662,000) for direct costs (plus indirect costs)
- Duration: Maximum period of performance is 2 years
Submission
Submission deadlines are not available until the Program Announcement(s) is released.
Further Information
- Requests for email notification of the Program Announcement(s) set to help@eBRAP.org
- Visit the website for this Program